Generate:Biomedicines, founded in 2018, is a biotechnology company and developer of a generative biology platform that seeks to use AI and machine learning to create pharmaceutical therapies on demand. Through its Generate Platform, the company aims to produce therapies for constantly changing clinical targets, with the goal of reducing the time and money required to respond to medical conditions. Generate:Biomedicines is headquartered in Somerville, Massachusetts.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/24/2024 | Series C | $288MM | $xx.xx | $1.95B | Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Fidelity, Flagship Pioneering, Maps Capital, March Capital, Novartis, Nventures, Pictet Alternative Advisors, T. Rowe Price | |
Price per Share
$xx.xx
Shares Outstanding
24,303,797
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abu Dhabi Investment Authority, Alaska Permanent Fund, Altitude Life Science Ventures, Amgen, Arch Venture Partners, Fidelity, Flagship Pioneering, Maps Capital, March Capital, Novartis, Nventures, Pictet Alternative Advisors, T. Rowe Price
|
||||||
11/18/2021 | Series B | $373.42MM | $xx.xx | $1.52B | Alaska Permanent Fund, Altitude Life Science Ventures, Arch Venture Partners, Flagship Pioneering, T. Rowe Price | |
Price per Share
$xx.xx
Shares Outstanding
31,512,642
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alaska Permanent Fund, Altitude Life Science Ventures, Arch Venture Partners, Flagship Pioneering, T. Rowe Price
|
||||||
09/10/2020 | Series A | $40.25MM | $xx.xx | $89.44MM | Flagship Pioneering | |
Price per Share
$xx.xx
Shares Outstanding
40,250,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering
|